“

We believe the FDA will likely view the risk as likely to be a class effect and apply changes to all approved drugs in the class, thus, even with information added to Onglyza's label for increased risk of heart failure hospitalization, we do not expect the drug to be commercially disadvantaged versus other members of its class.